IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke
- Conditions
- Upper Limb Spasticity After Stroke
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 45
- Registration Number
- NCT01239628
- Locations
- 🇧🇪
Heilig Hart Ziekenhuis, Lier, Belgium
🇧🇪AZ St-Jan, Brugge, Belgium
🇧🇪AZ Sint Lucas, Gent, Belgium
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
- Conditions
- Neuroendocrine TumorsCarcinoid Syndrome
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 340
- Registration Number
- NCT01234168
- Locations
- 🇨🇿
Hospital Pardubice, Pardubice, Czechia
🇫🇷CHU Angers, Angers, France
🇫🇷Hôpital Saint André, Bordeaux, France
Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 2
- Registration Number
- NCT01230970
- Locations
- 🇳🇴
Akershus University Hospital, Lørenskog, Norway
To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following Stroke
- Conditions
- Muscle Spasticity
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 469
- Registration Number
- NCT01020500
- Locations
- 🇫🇮
Department of Physical and Rehabilitation Medicine/Central Hospital of Central Finland (Site 246005), Jyväskylä, Finland
🇫🇮Invalidförbundets Rehabiliteringscenter i Lappland (Site 246004), Rovaniemi, Finland
🇫🇮Neurologiska Polikliniken, Tampere University Hospital (site 246001), Tampere, Finland
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 8
- Registration Number
- NCT01018953
- Locations
- 🇦🇹
University Hospital, Internal Medicine - Oncology, Vienna, Austria
🇮🇱Rabin Medical Center, Petah Tikva, Israel
🇷🇺Altay Regional Oncology dispensary, Barnaul, Russian Federation
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 339
- Registration Number
- NCT01020448
- Locations
- 🇪🇸
Hospital Juan Canalejo, Coruña, Spain
🇬🇧Lister Hospital, Stevenage, United Kingdom
🇫🇷Hôpital Pellegrin, Bordeaux, France
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 109
- Registration Number
- NCT00994214
- Locations
- 🇺🇸
Pituitary Center, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital / Neuroendocrine Unit, Boston, Massachusetts, United States
🇧🇪UZ Leuven, Leuven, Belgium
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 73
- Registration Number
- NCT00910091
- Locations
- 🇧🇪
Centre Jules Bordet, Bruxelles, Belgium
🇧🇪Onze-Lieve-Vrouwzickenhuis-Campus Aalst, Aalst, Belgium
🇫🇷Hôpital Jean Minjoz, Besançon, France
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 35
- Registration Number
- NCT00909844
- Locations
- 🇫🇷
Hôpital des Enfants, Toulouse, France
🇫🇷Hôpital Hôtel Dieu (CHU), Angers, France
🇫🇷Hôpital Flaubert, Le Havre, France
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
- Conditions
- IGF1 Deficiency
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 500
- Registration Number
- NCT00903110
- Locations
- 🇫🇷
Pole medical Bel'Air, Mulhouse, France
🇫🇷Centre Hospitalier de Blois, Blois, France
🇫🇷Hôpital Jean Verdier, Bondy, France